Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Synaptogenix
Location
1185 AVENUE OF THE AMERICAS
New York, New York, United States
About
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Synaptogenix raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
New YorkBiotechnologyHealth CareArtificial IntelligenceBlockchainCryptocurrencyTherapeuticsMachine Learning